Y-mAbs Therapeutics, Inc. YMAB
Set alert
At close · Sep 16
- Open
- 8.61
- Prev close
- 8.61
- Mkt cap
- 363.24M
- Vol
- 760.67K
- Avg vol
- 249.12K
- EPS
- -0.54
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.61
- High
- 8.61
- Forward P/E
- -13.98
- Beta
- 0.67
- Short ratio
- 13.91
- Inst. own
- 72.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 12.41
- 200-d avg
- 13.15
- 1y target
- 20.64
News
1 year ago zacks.com
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Y-mAbs Therapeutics, Inc. (YMAB) could be a good stock pick from a technical perspective. YMAB recently experienced a "golden cross" event, which saw its…
1 year ago globenewswire.com
Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating…
1 year ago benzinga.com
Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes
Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles.
1 year ago zacks.com
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.21 per share a year ago.
1 year ago businesswire.com
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals.…
1 year ago fool.com
Y-mAbs (YMAB) Q2 Revenue Falls 14%
Y-mAbs Therapeutics (YMAB), a biopharmaceutical company focused on developing and commercializing antibody-based cancer therapies, reported its second quarter 2025 results on August 8, 2025. The…
1 year ago globenewswire.com
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and…
1 year ago prnewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
NEW YORK , Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is…
1 year ago businesswire.com
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
1 year ago globenewswire.com
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and…
1 year ago zacks.com
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price…
1 year ago https://thefly.com
Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley upgraded Y-mAbs Therapeutics to Equal Weight from Underweight with a price target of $8.60, up from $7, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per…
1 year ago https://thefly.com
Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord
Canaccord downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $26, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
1 year ago https://thefly.com
Y-mAbs Therapeutics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Jeff Jones downgraded Y-mAbs Therapeutics without a price target to Perform from Outperform after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in…
1 year ago https://thefly.com
Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline
Brookline analyst Kemp Dolliver downgraded Y-mAbs Therapeutics to Hold from Buy with an $8.60 price target after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
1 year ago https://thefly.com
Y-mAbs Therapeutics downgraded to Hold from Buy at Truist
Truist downgraded Y-mAbs Therapeutics to Hold from Buy with a price target of $8.60, down from $14, after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago prnewswire.com
Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE , Aug. 5, 2025 /PRNewswire/ -- The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB…
1 year ago businesswire.com
YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) to SERB Pharmaceuticals for $8.60 per share in…
1 year ago globenewswire.com
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
Acquisition to Include Naxitamab-gqgk DANYELZA ® ( Naxitamab-gqgk) , Further Broadening SERB's Rare Oncology Product Portfolio Transaction Expands SERB's Investment in the U.S. SERB to Commence…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
1 year ago zacks.com
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
YmAbs Therapeutics (YMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
2 years ago benzinga.com
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
-
3 years ago benzinga.com
Earnings Scheduled For May 8, 2023
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 469 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 175 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
-
3 years ago benzinga.com
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
-
4 years ago benzinga.com
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 85 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 96 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also…
-
4 years ago benzinga.com
Why UserTesting Shares Are Trading Higher By Around 93%? Here Are 53 Stocks Moving In Thursday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) gained 111% to $2.03 after the company announced it entered into a license agreement with Transcosmos Digital Technology for its Apromore process…
-
4 years ago benzinga.com
Earnings Scheduled For August 8, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.
-
4 years ago benzinga.com
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning trading, 400 companies set new 52-week lows.